glp 1 analogues diabetes Dosage of GLP-1 Multifaceted Roles of GLP-1 and

Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)

Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience

Water volumes, unit conversions, titration schedules, and storage guidelines for accurate dosing.

A new study found that adults over the age of 60 and on a GLP-1 medication reduced their likelihood of developing dementia by 23 to 44%, depending which medication they were on.

When the overweight population is included, i.e